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Androgen-secreting ovarian tumours are extremely rare
accounting for <5% of all ovarian neoplasms. They are
more frequent in postmenopausal women and should be
suspected in the case of a rapid onset of androgenic
symptoms. We report 4 cases of postmenopausal women
who presented with signs of virilisation. All patients
revealed increased serum levels of testosterone, normal
dehydroepiandrosterone-sulfate and negative pelvic
ultrasound for adnexal masses. An androgen-secreting
ovarian tumour was suspected and all of them were
submitted to bilateral oophorectomy. Histology conﬁrmed
the diagnosis of Leydig cell tumours in 3 patients and
mature teratoma in 1. A successful response to surgery,
which includes a decline in serum androgen levels and
signs of hyperandrogenism, was observed in our
patients. This case series demonstrates that androgen-
secreting ovarian neoplasms may not be detectable by
imaging studies, but should be considered in the
differential diagnosis of all postmenopausal women with
signs of hyperandrogenism.
BACKGROUND
Androgen-secreting neoplasms of the ovary are a
rare cause of hyperandrogenism in women and
account for <5% of all ovarian neoplasms.1
Hyperandrogenism can result in a virilisation syn-
drome, which is characterised by clitoral hyper-
trophy, deepening of the voice, increased libido,
breast atrophy, severe hirsutism and male-pattern
baldness.1 2 These tumours should be suspected
when the onset of androgenic symptoms is sudden
and rapidly progressive,3 especially if associated
with signs of virilisation or defeminisation. In most
cases, hormonal abnormalities include increased
serum testosterone levels in the presence of normal
dehydroepiandrosterone-sulfate (DHEA-S).3
Among functional ovarian neoplasms, sex-cord
stromal tumours are the ones most commonly asso-
ciated with hyperandrogenism.3 According to the
WHO, Leydig cell tumours are classiﬁed in this
group and account for 0.1% of all ovarian
tumours.1 4
They are usually benign, small, solid and pre-
dominantly seen in postmenopausal women.4
Mature teratoma is the most frequent germ cell
tumour and a rare cause of androgen-secreting
ovarian neoplasm.2 It consists in tissues that recap-
itulate the ectoderm, endoderm and mesoderm. In
most cases, this tumour contains non-secreting
tissues, however very rarely can produce testoster-
one leading to a virilisation syndrome.5
In postmenopausal women, bilateral oophorec-
tomy is the preferred treatment, while in young
women in whom fertility is an issue, a unilateral
oophorectomy should be performed.
The prognosis for androgen-secreting neoplasms
of the ovary is generally good with completely
reversion of symptoms after surgery, although some
cases have been reported to be malignant.3
CASE PRESENTATION
We report four cases of postmenopausal women
presenting with several months’ history of progres-
sive facial and body hirsutism. Furthermore,
patients 2–4 presented with androgenic alopecia
and patient 3 with increased libido. No other viril-
isation signs, like enlarged muscle mass, deepening
of voice or clitoromegaly, were seen in all presented
cases.
Clinical, biochemical, radiological and histo-
logical features are presented in tables 1–3.
The virilising manifestations were rapidly pro-
gressive (1 year or less), except in patient 1, who
reported of progressive hirsutism for the last
3 years.
Appearance of a round and plethoric face coinci-
dent with the beginning of hirsutism was also
referred in patient 1 and a long history of central
obesity was observed in patients 2 and 4. Other
symptoms suggestive of hypercortisolism, including
lethargy, weakness, proximal myopathy, easy bruisa-
bility and purplish skin striae, were absent in all
cases.
Menarche and menopause had occurred at
proper ages and all patients referred regular men-
strual cycles and normal fertility. Personal medical
histories included hypertension, dyslipidaemia and
cervix-sparing hysterectomy for uterine ﬁbroids at
43 years (patient 1); hypertension, type 2 diabetes
and thyroid lobectomy for benign thyroid nodule
(patient 2); renal transplant due to polycystic
kidney disease and new-onset diabetes after trans-
plant (patient 3); and hypertension, ischaemic car-
diomyopathy and asthma (patient 4).
Only patient 2 was taking drugs with androgenic
effects (tacrolimus) for 5 years before the beginning
of hirsutism. Their families’ medical histories were
unremarkable.
Physical examination conﬁrmed signs of virilisa-
tion with facial and body hirsutism in all patients
and androgenic alopecia in all except patient 1.
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The severity of hirsutism was evaluated by a modiﬁed
Ferriman-Gallwey score, with patient 4 showing a mild and the
rest a moderate to severe hirsutism. A cervical polyp was found
during pelvic examination in patient 3. A round and plethoric
face was observed in patient 1. Patients 2 and 4 had central
obesity with a body mass index of 34.5 and 32.5 kg/m2, respect-
ively. No other features of Cushing syndrome, signs of enlarge-
ment of clitoris and palpable adnexal masses were observed.
INVESTIGATIONS
Endocrine evaluation revealed increased serum testosterone
and normal DHEA-S in all women (table 2). Gonadotropin
concentration was within the menopausal range, but
oestradiol was slightly elevated for postmenopause. The
17-hydroxyprogesterone (17 OHP) concentration was mildly ele-
vated in patients 1–3. An ACTH stimulation test was performed
in these patients with an appropriate 17 OHP response in all.
Cushing’s syndrome was reliably ruled out by the ﬁnding of
normal free urinary cortisol levels (patients 1, 2 and 4) and sup-
pression of morning plasma cortisol concentrations after overnight
dexamethasone test—serum cortisol 1.51 mg/dL (patient 2).
Serum tumour marker CA125 was evaluated in patients 1, 2
and 4 and was negative in all of them.
Pelvic ultrasound revealed no abnormal ﬁndings in all patients
except in patient 2 (table 3). In this woman, a computerised
axial tomography (CT) demonstrated homogeneous masses on
both ovaries and no other pathological ﬁndings were detected.
In patient 1, pelvic CT and MRI were performed, but no
ovarian or adrenal abnormalities were found.
TREATMENT
All patients underwent laparoscopic bilateral oophorectomy. A
simultaneous hysterectomy and removal of the uterine cervix
were also performed in patients 3 and 1, respectively.
Histological results revealed unilateral ovarian Leydig cell
tumours (ﬁgure 1) in patients 1–3, and a mature ovarian calci-
ﬁed teratoma containing bone tissue but no Leydig cells in
patient 4 (ﬁgure 2). No histological signs of malignancy were
identiﬁed.
OUTCOME AND FOLLOW-UP
During follow-up, all patients had an excellent response to
surgery with postoperative declines of serum androgens
(1–4 months) and signiﬁcant improvement of signs of hyperan-
drogenism (6–12 months). In patient 4, although androgen
levels had dropped to normal levels 1 month after surgery,
hirsutism did not regress until 3 years later.
DISCUSSION
Rapid onset of androgenic symptoms must raise the suspicion of
androgen-secreting tumours. There is still a limitation in under-
standing natural history, management and prognosis of these
tumours due to their rarity. Our case series introduces interest-
ing aspects for a better understanding of this kind of neoplasms.
First, we report a very rare aetiology for hyperandrogenism,
especially a testosterone-producing ovarian mature teratoma,
with only few published cases. Second, in all our patients, the
tumours were very small and imaging modalities were not able
to identify ovarian lesions, demonstrating that the diagnosis can
be challenging. In spite of its low incidence, androgen-secreting
tumours must be considered in postmenopausal women with
signs of virilisation.
Table 1 Clinical features
Patient 1 Patient 2 Patient 3 Patient 4
















Time of onset to
presentation (months)
36 12 8 12
Ferriman-Gallwey score 16 20 18 8
Table 2 Biochemical parameters determined before and after surgery
Result
Patient 1 Patient 2 Patient 3 Patient 4
Test (units/reference range) Before surgery After surgery Before surgery After surgery Before surgery After surgery Before surgery After surgery
LH (mUI/mL)
(11.3–40.0)
10.8 ND 25.3 ND 57 184 23 ND
FSH (mUI/mL)
(9.7–111.0)
43.7 ND 55.8 ND 121 158 79 ND
Total testosterone (ng/mL)
(0.04–0.6)
6.4 0.09 1.7 0.08 5.9 0.10 1.43 0.23
Free testosterone (pg/mL)
(0.03–1.55)
12.3 0.69 3.9 0.18 10.8 1.27 1.79 0.63
Oestradiol (pg/mL)
(<30)
60 ND 35 ND 40 26 30 ND
Androstenedione (ng/mL)
(0.3–3.3)
2.26 1.42 2.4 1.01 >10 1.13 2.23 1.07
DHEAS (mg/dL) 204 (9–246) 108 (9–246) 45 (9–246) 42 (9–246) 109 (35–430) 20 (35–430) 20 (35–430) <15 (35–430)
17 OHP (ng/mL)
(0.2–1.7)
2.3 0.51 2.9 0.5 4.2 0.35 1.17 1.01
17 OHP (ng/mL) 600 after
ACTH stimulation test
6.2 ND 5.8 ND 6.4 ND ND ND
17 OHP, 17 hydroxyprogesterone; ACTH, Adrenocorticotropic hormone; DHEA-S, dehydroepiandrosterone-sulfate; FSH, follicle-stimulating hormone; LH, luteinizing hormone; ND, not
done.
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After menopause, ovarian causes of virilisation are more
common than adrenal ones.6
Systematic investigation (hormonal and radiological) is essen-
tial to establish the right diagnosis.7 The measurement of serum
androgens is important to differentiate between ovarian or
adrenal source.8 Marked elevation of testosterone levels, espe-
cially above 200 ng/dL (2 ng/mL), should raise the suspicion of
an androgen-producing tumour (adrenal or ovary).3 A normal
serum level of DHEA-S typically excludes an adrenal cause,
while a value <600 mg/dL makes an adrenal neoplasm the most
probable diagnosis.9
Ultrasound is generally the initial imaging choice for evaluat-
ing ovarian tumours in the presence of hyperandrogenaemia.
CT and MRI scanning can also be used for the diagnosis of
adnexal or adrenal masses.10
Similar to other cases reported in the literature, symptoms of
hyperandrogenism were the main initial clinical features in our
patients. The postmenopausal onset and progressive virilisation
had raised suspicion for an androgen-secreting tumour. The hor-
monal tests suggested an ovarian source, since serum hormone
assay showed high levels of testosterone with normal levels of
DHEA-S.9 Circulating levels of androstenedione and 17 OHP
can also be elevated in androgen-secreting neoplasms, because
some tumours may predominantly secrete these testosterone
precursors.9 Morning serum 17 OHP concentration was
increased in all patients, except patient 4, who presented a
mature teratoma. Increased 17 OHP serum levels may also be
suggestive of non-classical congenital adrenal hyperplasia due to
21-hydroxylase deﬁciency and some cases have been reported in
patients with Leydig cell tumours.9 Therefore, ACTH stimula-
tion tests (17 OHP measured 1 hour after 250 mg intravenous
synthetic ACTH) were performed in patients 1–3, which
excluded this diagnosis. In the presence of clinical features of
Cushing’s syndrome, a focused investigation should be included
in the evaluation of hypercortisolism as a possible cause of viril-
isation. The occurrence of facial plethora and hypertension in
patient 1 and central obesity in patients 2 and 4 raised that sus-
picion. Twenty-four-hour urinary cortisol and overnight dexa-
methasone suppression tests were performed, which ruled out
this diagnosis.
A Leydig stromal cell tumour is a rare ovarian tumour that
belongs to the group of sex-cord stromal tumours and accounts
for <0.1% of all ovarian tumours.1 3 More than 75% of
patients show signs of virilisation, resulting from autonomous
androgen secretion. These tumours are usually benign, unilat-
eral, characterised by steroid cell proliferation and located
within the ovarian stroma.3 9 The small size (usually <3 cm)
contributes for the poor visualisation on ultrasound and CT
scanning.2 This tumour is distinguished from the Sertoli-Leydig
cell tumour by the absence of a sex-cord component.
Patients 1–3 were diagnosed with Leydig cell tumours. The
absence of radiological signs of ovarian tumours (patients 1 and
3) and a lack of diagnostic concordance between radiology and
histology (patient 2) probably reﬂect the small size of these
tumours.
Oestradiol levels were slightly increased in all patients, which
were eventually explained by peripheral conversion of andro-
gens to oestrogens through aromatase activity. The endometrial
thickening observed in patient 2 could have the same explan-
ation. Although rare, in the literature, these tumours have been
associated with a hyperestrogenic state and can present with
vaginal bleeding, endometrial hyperplasia and carcinoma.1
Table 3 Radiological and histological features
Patient 1 Patient 2 Patient 3 Patient 4
Pelvic
ultrasound
No abnormalities Endometrial thickening; enlargement of
both ovaries
No abnormalities No abnormalities
Pelvic CT Normal Homogeneous masses of LO (26 mm) and
RO (28 mm)
ND ND
Pelvic MRI Polypoid lesion of uterine cervix ND ND ND
Treatment Bilateral oophorectomy+removal of the
uterine cervix
Bilateral oophorectomy Bilateral oophorectomy+
hysterectomy
Bilateral oophorectomy
Histology Leydig cell tumour RO (17 mm) Leydig cell tumour LO (10 mm) Leydig cell tumour RO (15 mm) Mature teratoma tumour LO
(15 mm)
LO, left ovary; ND, not done; RO, right ovary.
Figure 1 An ovarian Leydig cell tumour (Patient 1). Section shows
groups of Leydig cells. H&E, ×100.
Figure 2 Mature ovarian calciﬁed teratoma containing bone tissue
(patient 4). H&E, ×400.
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Mature teratomas account for more than 95% of all ovarian
teratomas and are almost invariable benign.5 Although
testosterone-producing mature teratomas with isolated virilisa-
tion have been described, they are extremely rare with only few
cases published.2 The presenting case of patient 4 was diagnosed
with mature teratoma with no Leydig cells found on histology
examination. However, a normalisation of androgen levels soon
after surgery conﬁrmed it was the source of hyperadrogenism.
Teratomas can present as a solid or cystic mass and usually have
a characteristic ultrasound appearance (areas of fat and calciﬁca-
tion), which allow reasonably accurate diagnosis in many cases.5
In our patient, the small size and low fat content could explain
why the tumour was not detected by image techniques.
According to National Comprehensive Cancer Network
(NCCN) guidelines, germ cell and sex-cord stromal tumours are
rare ovarian cancer histologies, which can be either benign or
malignant, being stage and degree of differentiation their most
important prognostic factors.11
Deﬁnitive treatment of androgen-secreting ovarian tumours
depends on histology subtype, stage of the disease and desiring
to preserve the fertility. Once Leydig cell tumours and mature
teratoma of the ovary are almost invariable benign, surgery is
the ﬁrst-line treatment suggested in NCCN guidelines and adju-
vant therapy is not considered in the majority of these
tumours.11 In postmenopausal women, bilateral oophorectomy
is the preferred treatment. In younger women whose fertility
preservation is an issue and when imaging studies are negative
or inconclusive, selective ovarian vein catheterisation should be
performed in order to establish the ovarian androgen-secreting
source. Given that all our patients were in menopause, bilateral
oophorectomy was performed without further presurgical
examination.
Histology and postoperative declines in serum androgens pro-
vided a deﬁnite diagnosis in all patients. Pure Leydig cells are
well-differentiated tumours and to the best of our knowledge,
all the reported cases had an excellent prognosis. Although a
rare malign transformation can occur in 0.2–2% of patients
with mature teratomas, these tumours are usually benign and
have a good prognosis, with regression of virilisation after
surgery.12 13 All our patients had a very good response to
surgery with no signs of recurrence after 5 years of follow-up.
CONCLUSION
Androgen-secreting ovarian tumours are extremely rare, but
should be considered in all postmenopausal women with signs
of hyperandrogenism, even when imaging studies are negative.
The diagnosis is usually challenging and surgery is recom-
mended as a diagnostic test and deﬁnitive treatment.
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Learning points
▸ Rapid onset of androgenic symptoms, especially if
associated with signs of virilisation or defeminisation, must
raise the suspicion of an androgen-secreting tumour.
▸ High levels of testosterone with normal levels of the DHEA-S
suggest an ovarian source.
▸ Androgen-secreting neoplasms of the ovary should be
considered in all postmenopausal women with signs of
hyperandrogenism, even when imaging studies are negative.
▸ Oophorectomy is recommended as a diagnostic test and
deﬁnitive treatment.
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